Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (15986)	8/15/2002 8:16:20 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Cacaito, do you remember what sent Xoma down sharply? April 5, 2002 -- Genentech and XOMA Obtain Results from Xanelim(tm) (Efalizumab) Pharmacokinetic Study Data showing that the two Xanelim's were not identical, was available to the consultant and that was indeed negative information since many assumed the P.K. study was no big deal. It just provides one more reason why companies should disclose to shareholders more information asap, since leaks are going to occur. BTW just because a reporter says, "Xoma stock dropped 42% in April when the drug trial results were publicized" does not make it true. Note the reporter said the drug trial results but it was the P.K. results, end of story.